You are here

Atorvastatin Gains New Indication, Reduces Heart Attack Risk

NEW YORK, Aug. 4 /PRNewswire-FirstCall/ -- Pfizer Inc said today that the U.S. Food and Drug Administration has approved its cholesterol-lowering therapy Lipitor(R) (atorvastatin calcium) for the prevention of cardiovascular disease by reducing heart attack risk in people with normal to mildly elevated cholesterol levels who have other cardiovascular risk factors.

The FDA's decision was based on the findings of the landmark ASCOT trial (Anglo-Scandinavian Cardiac Outcomes Trial), which found that the lowest dose of Lipitor (10 mg) reduced the relative risk of heart attack by 36 percent compared to placebo. Because these significant benefits were seen so early, the trial was ended nearly two years ahead of schedule.

"No other lipid-lowering agent has shown an effect as dramatic as Lipitor in terms of reducing cardiovascular disease and in offering this significant health benefit as fast as Lipitor," said Dr. Joseph Feczko, Pfizer's President of Worldwide Development. "Lipitor clearly is different in its early ability to reduce heart attacks among a very broad population of patients, regardless of cholesterol levels."

Another Lipitor study also ended two years ahead of schedule and also demonstrated Lipitor's early cardiovascular benefits to patients. The CARDS study (Collaborative Atorvastatin Diabetes Study), the largest study ever designed to evaluate a statin in diabetics, showed that patients with diabetes who took Lipitor had 48 percent fewer strokes than those who received placebo. In addition, Lipitor-treated patients had significantly fewer fatal and non- fatal heart attacks and required fewer surgical procedures.

Heart disease is the leading cause of death in the United States, and most Americans with elevated cholesterol, a leading risk factor for heart attacks, are either not diagnosed or have not reached their target LDL levels with medication. "People are suffering heart attacks and dying unnecessarily," Dr. Feczko said. "With Lipitor, we have a medicine that can significantly reduce cardiovascular disease for millions of patients."

Lipitor also is the first lipid-lowering agent to demonstrate superior cardiovascular benefits when compared to another statin in two separate studies. In the REVERSAL study, Lipitor halted the progression of atherosclerosis, or hardening of the arteries, while the other statin merely slowed progression. Pfizer has either submitted these additional studies to the FDA or plans to do so shortly for inclusion in the product's prescribing information.

In the PROVE-IT study, patients taking Lipitor had a significantly lower cardiovascular events rate than patients taking a different statin. PROVE-IT was conducted by the Bristol-Myers Squibb Co.

"It's becoming increasingly clear that Lipitor provides cardiovascular benefits beyond simply lowering LDL cholesterol," Dr. Feczko said. "Lowering LDL levels with statin therapy has been shown to reduce death and disability, but based on recent studies, we now know that Lipitor provides earlier and greater benefits than lowering LDL alone."

With starting doses of 10 mg, 20 mg or 40 mg, 98 percent of patients taking Lipitor reach their target LDL goal level. Updated guidelines recently issued by the National Cholesterol Education Program confirm the added benefit of prescribing cholesterol-lowering medication like Lipitor, along with diet modification and exercise, to patients at risk for cardiovascular disease. The NCEP panel cited the ASCOT trial as one of the landmark studies instrumental in concluding the revision of the guidelines.

Every year, more than 865,000 Americans suffer heart attacks. High blood pressure and elevated cholesterol are the leading risk factors for heart disease but other factors compound the risk, including family history of heart disease, age over 55, smoking, diabetes, obesity and lack of exercise. Direct (medical costs) and indirect (lost productivity) costs related to coronary heart disease are expected to exceed $133 billion this year.

Lipitor is the leading cholesterol-lowering therapy in the world with more than 76 million patient years of experience. Since the introduction of Lipitor seven years ago, its safety and effectiveness have been supported through the Atorvastatin Landmark Program(TM), an extensive clinical program with more than 400 ongoing and completed trials involving more than 80,000 patients.

Lipitor(R) (atorvastatin calcium) is a prescription drug used with diet to lower cholesterol and to reduce the risk of heart attacks. Lipitor is not for everyone, including those with liver disease or possible liver problems, women who are nursing, pregnant, or may become pregnant.

Patients who take Lipitor should tell their doctor about any unusual muscle pain or weakness. This could be a sign of serious muscle side effects. Patient should also inform their doctor about any medications they are currently taking to avoid possible serious drug interactions. Prescribing physicians should do simple blood tests to monitor liver function before and during drug treatment. The most commonly reported side effects are gas, constipation, stomach pain, and indigestion. They are usually mild and tend to go away.

For full prescribing information, please visit https://www.lipitor.com/ or call 1-888-LIPITOR.

Source: Pfizer, Inc.

Recent Headlines

Patients Had Improved Lung Function, Fewer Exacerbations
Particularly Serious: Antidepressants, Drugs for Parkinson’s and Epilepsy
Drug “Remarkably Effective” at Killing Range of Gram-Positive Bacteria
Up to 70% Greater Risk of Bacterial Infection, 48% Risk for Fungal Infection
Record-High Number of Cases in France, Italy, Greece, Other Locations
Will Have a Longer Shelf Life Than Current, Expired Stockpile
Most Women Undergoing Surgery for Suspected Cancer Do Not Have It
Specific Monoclonal Antibodies Ensure Extreme Sensitivity, Accuracy